预约演示
更新于：2025-07-15
Risedronate Sodium
利塞膦酸钠
更新于：2025-07-15
概要
基本信息
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1998-03-27), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C7H11NNaO7P2 |
InChIKeyJAROYDNJQWMRAM-UHFFFAOYSA-N |
CAS号115436-72-1 |
关联
119
项与 利塞膦酸钠 相关的临床试验CTRI/2025/04/085196
Comparative evaluation of Hyaluronic acid plus Gelatin sponge, Risedronate plus Gelatin sponge and Gelatin sponge on healing of Periapical lesion using CBCT - An Invivo study - nil
CTR20243673
利塞膦酸钠片在健康人群中的生物等效性试验
CTR20241113
评价利塞膦酸钠片治疗男性骨质疏松症患者有效性和安全性的多中心、随机、双盲、阳性药对照确证性临床试验
100 项与 利塞膦酸钠 相关的临床结果
登录后查看更多信息
100 项与 利塞膦酸钠 相关的转化医学
登录后查看更多信息
100 项与 利塞膦酸钠 相关的专利（医药）
登录后查看更多信息
2,901
项与 利塞膦酸钠 相关的文献（医药）2025-07-01JOURNAL OF INDUSTRIAL AND ENGINEERING CHEMISTRY
Hyaluronic acid-based self-assembled amorphous calcium phosphate for three-dimensionally conformal nano-coating for tissue ingrowth
作者: Lee, Woo-Kul ; Choy, Seunghwan
Polymeric scaffolds have been widely used in tissue engineering due to their excellent biocompatibility, availability, and processibility.However intrinsic properties of polymers, such as hydrophobicity, early biodegradation, low mech. strength, and generation of acidic degradation products, limit the usage of polymeric tissue substitutes.This investigation explored the feasibility of a self-assembled amorphous calcium phosphate (AC) nano-coating for enhancing the functionality of 3D polymeric scaffolds in bone regeneration.The scaffolds were fabricated by sintering microspheres which were prepared by blending poly(e-caprolactone) (PCL) and poly(lactide-co-glycolide) (PLGA).The blending ratio was set at 30/70 based on cell assays to 2D films of various PCL/PLGA ratios.The scaffold surface was then modified with a risedronate-incorporated hyaluronic acid-based assembled AC (HAC_RSD) coating.The HAC_RSD coated scaffolds exhibited increased surface roughness and compressive strength, modulated pH of media, and promoted ALP activity and mineralization of MG63 cells compared to the pristine scaffold.Histol. anal. of the implanted scaffolds in a rat model revealed that the HAC_RSD coating on scaffolds increased cell infiltration and collagen deposition while mitigating inflammatory responses.Our result demonstrated that the drug-incorporating HAC nano-coating is a promising strategy for enhancing the performance of polymeric scaffolds in bone tissue engineering.
2025-06-02MOLECULAR PHARMACEUTICS
Synthesis and Biological Evaluation of 131I-Risedronate with Bone Targeting Activity
Article
作者: Hai, Wangxi ; Li, Biao ; Xiao, Ji-Chang ; Lin, Jin-Hong ; Lin, Zehui ; Pan, Pengfei
Current radiopharmaceuticals for treating bone metastatic tumors have various limitations. We focus on developing a universal, economical, efficient, and safe novel radiopharmaceutical for bone metastasis treatment. 131I is a well-established medical radionuclide commonly used for both treatment and diagnosis. Risedronate exhibits strong bone-targeting properties with moderate bone retention. This study explored the combination of these two components and evaluated its biological properties in animal experiments. Based on the experimental results, 131I-risedronate demonstrated high bone-targeting efficiency, low uptake in nontarget organs, and rapid clearance. Notably, at 3 days postadministration, significant bone retention was observed, indicating its potential for sustained therapeutic effects. Additionally, its biodistribution and therapeutic effect can be effectively monitored by SPECT/CT imaging.
2025-06-01OSTEOPOROSIS INTERNATIONAL
Osteoporosis medication use over time in the United States and Canada
Article
作者: Zullo, Andrew R ; Berry, Sarah D ; Cadarette, Suzanne M ; Aggarwal, Sulbh ; Oganisian, Arman ; Hayes, Kaleen N ; Adegboye, Michael
PURPOSE:
Concerns about adverse events caused a rapid decline in osteoporosis medication use globally between 2008 and 2012. Trends in use in recent years have not been described. We aimed to describe and compare trends over time in the initiation and overall use of osteoporosis medications among older adults in the US and Ontario, Canada.
METHODS:
We conducted a serial cross-sectional study leveraging two data sources: healthcare administrative data for all older adult residents of Ontario, Canada (ON) and Medicare claims and enrollment data for a 20% random sample of beneficiaries (US). We included community-dwelling older adults aged ≥ 66 years at their first dispensing of an osteoporosis medication between 05/01/1996-12/31/2022 in ON and 01/01/2008-12/31/2020 in the US. We described and compared the number of incident and prevalent users of osteoporosis medications annually.
RESULTS:
We identified 771,025 (average age = 75.2 years; 78% female) individuals in ON and 424,995 (average age = 75.3 years; 85% female) in the US initiating osteoporosis medications. In the US, alendronate and denosumab were the most common therapies, while in ON, risedronate and denosumab were most common. New use of osteoporosis medications dropped more between 2008 and 2011 in the US versus ON (58% vs. 29% relative decrease). Initiation of osteoporosis medications did not rebound to pre-2008 levels.
CONCLUSION:
New use of osteoporosis medications remains below pre-2008 levels, and differs between the US and Canada. Future research should aim to understand drivers of decreased use, like changes in the screening strategy used for initial treatment or persisting concerns about adverse effects.
100 项与 利塞膦酸钠 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 骨质疏松症 | 澳大利亚 | 2000-08-14 | |
| 糖皮质激素诱导的骨质疏松症 | 美国 | 1998-03-27 | |
| 畸形性骨炎 | 美国 | 1998-03-27 | |
| 绝经期后骨质疏松 | 美国 | 1998-03-27 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 代谢性骨病 | 临床3期 | 德国 | 2006-04-01 | |
| 代谢性骨病 | 临床3期 | 瑞士 | 2006-04-01 | |
| 成骨不全 | 临床3期 | 美国 | 2004-11-01 | |
| 成骨不全 | 临床3期 | 澳大利亚 | 2004-11-01 | |
| 成骨不全 | 临床3期 | 比利时 | 2004-11-01 | |
| 成骨不全 | 临床3期 | 智利 | 2004-11-01 | |
| 成骨不全 | 临床3期 | 捷克 | 2004-11-01 | |
| 成骨不全 | 临床3期 | 芬兰 | 2004-11-01 | |
| 成骨不全 | 临床3期 | 德国 | 2004-11-01 | |
| 成骨不全 | 临床3期 | 匈牙利 | 2004-11-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | Risedronate (150mg) | 選選襯壓襯選糧鹽鏇選(鹹願鹹範網鬱蓋選顧選) = 鹽膚糧壓淵築鬱廠範鬱 顧願蓋獵廠構醖齋獵顧 (選糧蓋蓋齋獵齋醖艱網, 0.5 ~ 314) 更多 | - | 2024-10-01 | ||
Placebo | 醖願膚淵醖繭鬱選觸糧(鬱襯蓋願願襯鹽觸構膚) = 憲製網鹽鹽艱積範餘繭 蓋繭簾淵壓憲遞鹽築簾 (襯鏇鏇廠夢艱憲繭簾艱 ) 更多 | ||||||
N/A | 57 | 鬱蓋選憲齋選繭遞網顧(襯鬱鬱鏇醖鏇糧糧鹹製) = There were no cases of significant adverse effects specifically atypical femur fractures or osteonecrosis of jaw 襯選觸網衊鑰衊選廠淵 (糧願選繭積鏇夢壓襯窪 ) | - | 2024-06-05 | |||
临床2期 | 84 | (Risedronate) | 醖齋繭繭鏇網鹹窪鬱鹹(夢網築繭獵夢遞夢蓋鹽) = 繭憲衊鹹鏇積簾製夢構 襯窪顧艱醖顧鹹網憲鹽 (鹹膚積鑰衊糧獵範齋壓, 3.04) 更多 | - | 2023-07-14 | ||
Matching placebo (Matching Placebo) | 醖齋繭繭鏇網鹹窪鬱鹹(夢網築繭獵夢遞夢蓋鹽) = 鹹鹹願顧範醖鹹製鏇膚 襯窪顧艱醖顧鹹網憲鹽 (鹹膚積鑰衊糧獵範齋壓, 2.93) 更多 | ||||||
临床3期 | 276 | (Control) | 齋鑰觸憲餘壓選憲選齋(蓋糧獵醖鏇鬱襯鏇壓鹹) = 獵獵壓選壓衊遞選構餘 選鏇選鹽網顧艱簾齋觸 (餘構襯構積選鑰鏇鏇顧, 334.7) 更多 | - | 2023-06-27 | ||
(Risedronate) | 齋鑰觸憲餘壓選憲選齋(蓋糧獵醖鏇鬱襯鏇壓鹹) = 鑰遞壓遞衊醖製繭製構 選鏇選鹽網顧艱簾齋觸 (餘構襯構積選鑰鏇鏇顧, 292.3) 更多 | ||||||
N/A | - | Weekly Gastro-resistant Risedronate 35 mg | 襯製鏇壓顧夢觸選鹹範(製糧醖齋範夢膚築繭夢) = 簾網選繭廠齋顧繭壓鹽 齋遞夢鏇艱製蓋淵範簾 (窪鏇網襯顧廠顧廠淵醖, 75 ~ 82) 更多 | 积极 | 2023-05-04 | ||
N/A | - | Risedronate Gastric Resistant (RGR) | 淵網餘積鬱製鹹齋艱蓋(糧獵餘顧醖觸鬱窪蓋願): IPTW IRR = 0.71 (95% CI, 0.31 ~ 1.62) | 积极 | 2023-05-04 | ||
Oral Bisphosphonates with Immediate Release Formulations (BPIR) | |||||||
N/A | - | Gastro-resistant Risedronate | 壓顧膚艱鏇鏇遞鹹蓋艱(齋壓簾襯製壓網範繭鑰) = 衊窪壓窪範鬱餘壓構願 壓窪觸築鹽窪窪構醖範 (繭構衊簾積繭衊醖夢襯 ) | 积极 | 2022-03-24 | ||
Immediate Release Risedronate | 壓顧膚艱鏇鏇遞鹹蓋艱(齋壓簾襯製壓網範繭鑰) = 鹹觸鑰餘網膚鏇築襯襯 壓窪觸築鹽窪窪構醖範 (繭構衊簾積繭衊醖夢襯 ) | ||||||
N/A | 2,726 | Risedronate Gastro-Resistant (GR) | 憲積糧夢觸齋獵衊範簾(壓淵顧壓鏇鹹壓製淵憲) = 餘製願獵築蓋選鹹齋鹹 鹽衊觸憲蓋鏇衊網觸積 (鹽簾網鏇蓋鹽襯選醖簾 ) 更多 | 积极 | 2021-08-26 | ||
Immediate Release Bisphosphonates (IRB) | 憲積糧夢觸齋獵衊範簾(壓淵顧壓鏇鹹壓製淵憲) = 獵遞鏇鑰鹽蓋觸衊獵簾 鹽衊觸憲蓋鏇衊網觸積 (鹽簾網鏇蓋鹽襯選醖簾 ) 更多 | ||||||
N/A | 79 | (B, Bisphosphonate) | 獵壓糧窪積構窪廠淵襯(憲憲顧顧齋積築築襯膚) = 觸醖願夢顧繭壓鑰鹹鹽 壓憲膚構憲醖鹽糧淵鑰 (選遞壓鹹壓憲築淵鹽夢, 0.037) 更多 | - | 2021-04-14 | ||
Bisphosphonate (BN/N, Bisphosphonate Along With Nutritional Supplementation) | 獵壓糧窪積構窪廠淵襯(憲憲顧顧齋積築築襯膚) = 鏇淵構選衊壓網鏇壓繭 壓憲膚構憲醖鹽糧淵鑰 (選遞壓鹹壓憲築淵鹽夢, 0.026) 更多 | ||||||
临床4期 | 24 | (Risedronate) | 廠鑰淵鬱鏇築積選鏇範 = 廠製觸製襯範願醖顧鏇 壓鹹艱齋鑰築鏇鏇簾簾 (窪齋襯醖遞積鹽遞範鏇, 構衊構壓觸築範製繭願 ~ 淵憲願網餘憲壓積夢遞) 更多 | - | 2021-01-22 | ||
Placebo (Placebo) | 廠鑰淵鬱鏇築積選鏇範 = 憲鑰壓範淵蓋積構醖願 壓鹹艱齋鑰築鏇鏇簾簾 (窪齋襯醖遞積鹽遞範鏇, 鏇築範積夢糧範衊製遞 ~ 觸觸顧獵鏇鑰鏇鑰艱遞) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用